Christina Nguyen, PA
Medical · Mint Hill, NCNPI 1538873799
Payments from drug & device makers
Across 98 payments — averaging $18.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$383
- AstraZeneca$208
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$149
- Bayer$130
- Mylan Specialty L.p.$112
- Lilly USA, LLC$111
- plus $688 from 19 others
What the payments were for
- Food & beverage$1,73397%
- Education$493%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 24 | $383 |
| AstraZeneca | 13 | $208 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $149 |
| Bayer | 8 | $130 |
| Mylan Specialty L.p. | 4 | $112 |
| Lilly USA, LLC | 7 | $111 |
| Sumitomo Pharma America, Inc. | 4 | $87 |
| Exact Sciences | 4 | $80 |
| Pfizer | 4 | $73 |
| Corcept Therapeutics | 3 | $66 |
| Merck | 3 | $50 |
| Ardelyx, Inc. | 2 | $47 |
| Boehringer Ingelheim | 2 | $45 |
| Novartis | 2 | $33 |
| Astellas Pharma US Inc | 2 | $31 |
| Daiichi Sankyo Inc. | 1 | $22 |
| GSK | 1 | $21 |
| Paratek Pharmaceuticals, Inc. | 1 | $20 |
| Lundbeck LLC | 1 | $20 |
| Xeris Pharmaceuticals, Inc. | 1 | $18 |
| Esperion Therapeutics, Inc. | 1 | $17 |
| Endo Pharmaceuticals Inc. | 1 | $17 |
| Axsome Therapeutics, Inc. | 1 | $16 |
| Amgen | 1 | $14 |
| Grifols USA, LLC | 1 | $13 |
How this compares
$1,782 in reported general payments places this provider in the 75th percentile of 878 medical providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 39 | $45,191 |
| FarxigaDapagliflozin Propanediol | 34 | $26,424 |
| EliquisApixaban | 15 | $21,440 |
| LinzessLinaclotide | 25 | $20,709 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 19 | $17,413 |
| MyrbetriqMirabegron | 12 | $14,773 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $14,619 |
| MounjaroTirzepatide | 13 | $13,287 |
| Tresiba Flextouch U-100Insulin Degludec | 22 | $9,423 |
| BelsomraSuvorexant | 12 | $5,171 |
| SymbicortBudesonide/Formoterol Fumarate | 14 | $3,585 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 112 | $3,014 |
| Rosuvastatin Calcium | 172 | $2,658 |
| Omeprazole | 146 | $2,490 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $2,200 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Levemir | $383 | $47,16751 claims |
| AstraZenecaFarxiga, Symbicort | $208 | $30,00948 claims |
| PfizerEliquis | $73 | $21,44015 claims |
| GSKTrelegy Ellipta | $21 | $17,41319 claims |
| Astellas Pharma US IncMyrbetriq | $31 | $14,77312 claims |
| Lilly USA, LLCMounjaro | $111 | $13,28713 claims |
| MerckBelsomra | $50 | $5,17112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 878 medical providers in North Carolina.
Other medical in Mint Hill
- Grace McLaurinHickory$553K
- Joel ThompsonCharlotte$269K
- Virginia JethroCary$213K
- Payal Soni-PatelAsheville$76K
- William JarrettElkin$59K
- Amanda ZimmermanWinston Salem$48K
- David TaylorMorehead City$40K
- Katherine CardSalisbury$39K
- John RobbinsWinston Salem$26K
- Ashley TipperStatesville$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.